Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial

Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-.ALPHA.

“…This result is particularly impressive considering that usually rosiglitazone treatment has the tendency to slightly but significantly increase LDL-C in diabetic patients (33,34). At 6 months only the telmisartan-treated patients experienced a significant improvement in glucose homeostasis parameters (HbA1c = −10.5%, FPG = −9.7%, HOMA index = −16.7%) and in overweight-related parameters (TNF-α = −16.1%, leptin = −15.4%).…”

Blood Pressure Control and Inflammatory Markers in Type 2 Diabetic Patients Treated with Pioglitazone or Rosiglitazone and Metformin

“…The beneficial effect of thiazolidinediones on glycemic control in diabetic subjects was already known (24,25) and was further confirmed by our actual study: the association of metformin with both pioglitazone and rosiglitazone significantly improved glycemic control in the studied subjects: we observed mean improvements of 16.5% in HbA1c plasma level (p< 0.01), 13.3% in FPG (p< 0.01), 14.1% in PPG (p< 0.01) and 23.2% in PPI (p< 0.05), with no significant differences between treatment groups. We confirmed the findings of previous studies (21,22) that pioglitazone appears to have a better effect on plasma lipid levels (total cholesterol [TC]=−9.8%, low-density lipoprotein cholesterol [LDL-C]=−6.9%, high-density lipoprotein cholesterol [HDL-C]=+9.1%, TG = −25.0%) than rosiglitazone (TC= +4.2%, LDL-C= +2.6%, TG = +1.7%).…”

Effects of Rosiglitazone on Lipids, Adipokines, and Inflammatory Markers in Nondiabetic Patients With Low High-Density Lipoprotein Cholesterol and Metabolic Syndrome

“…metabolic response to rosiglitazone may evolve over a 1-year period of time. 9 Last, our study was also limited by the inclusion of a small number of women.…”